Online inquiry

IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4257MR)

This product GTTS-WQ4257MR is a type of mRNA modified with 5-Methyl-CTP, which ecodes the monoclonal antibody that targets Factor VIII substitute gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000132.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2157
UniProt ID P00451
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ4257MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15494MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-7665
GTTS-WQ8005MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GZ-402668
GTTS-WQ4717MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BOS161721
GTTS-WQ11358MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI-551
GTTS-WQ7685MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GEN3013
GTTS-WQ12613MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ6544MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA D2E7
GTTS-WQ12021MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MM-302
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW